Vogg, Barbara
Novartis (Switzerland) · Novartis Institutes for BioMedical Research
2 papers on CoChatORCID 0009-0004-5563-8631
Most cited papers
- Verified
The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., et al. (2018) · EMBO Molecular Medicine
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 177
- Verified
A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
Neumann, U., Rueeger, H., Machauer, R., Veenstra, S. J., Lueoend, R. M., Tintelnot-Blomley, M., Laue, G., Beltz, K., Vogg, B., Schmid, P., et al. (2015) · Molecular Neurodegeneration
Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases
Cited by 113
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free